Camp4 Therapeutics (CAMP) Cash & Equivalents (2023 - 2026)

Camp4 Therapeutics' Cash & Equivalents history runs 4 years deep, the most recent figure standing at $99.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 101.24% year-over-year to $99.2 million; the TTM figure through Mar 2026 stood at $99.2 million (up 101.24% YoY), while the FY2025 annual figure was $109.5 million, up 71.02% from the prior year.
• Cash & Equivalents came in at $99.2 million for Q1 2026 at Camp4 Therapeutics, down from $109.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $109.5 million in Q4 2025 to a low of $2.5 million in Q3 2024.
• A 4-year average of $58.6 million and a median of $50.5 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 94.99% in 2024 and surged 2878.64% in 2025, its largest moves.
• Camp4 Therapeutics' Cash & Equivalents stood at $38.4 million in 2023, then soared by 66.86% to $64.0 million in 2024, then surged by 71.02% to $109.5 million in 2025, then retreated by 9.41% to $99.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $99.2 million, $109.5 million, and $75.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison